Design Therapeutics, Inc. $DSGN

What the company doesAI summary of filing

Design Therapeutics is a clinical-stage biopharmaceutical company developing GeneTAC molecules, a novel class of small-molecule therapeutics designed to treat inherited nucleotide repeat expansion diseases by modulating gene expression at the site of disease-causing mutations. The company has four main programs in clinical or late preclinical development: DT-216P2 for Friedreich ataxia (currently in Phase 1/2 trials), DT-168 for Fuchs endothelial corneal dystrophy (in Phase 2 biomarker trials), DT-818 for myotonic dystrophy type-1 (planning Phase 1 trials in 2026), and HD GeneTAC candidate molecules for Huntington's disease (in preclinical studies). The company is pre-revenue and finances its operations through equity funding, with no approved products or commercial revenue to date. [10-K 2026-03-09]

Segments: DT-216P2 (Friedreich ataxia), DT-168 (Fuchs endothelial corneal dystrophy), DT-818 (Myotonic dystrophy type-1), HD GeneTAC candidates (Huntington's disease)